AXSM - Axsome Therapeutics, Inc.
IEX Last Trade
86.84
-0.050 -0.058%
Share volume: 11,114
Last Updated: Fri 27 Dec 2024 08:29:52 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$86.89
-0.05
-0.06%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-09 | 2022-11-07 | 2023-02-28 | 2023-05-09 | 2023-08-07 | 2023-11-06 | 2024-02-23 | 2024-05-06 | |
Assets | |||||||||
Total Assets | 180.559 M | 338.958 M | 331.476 M | 389.179 M | 611.638 M | 600.857 M | 588.236 M | 545.728 M | |
Current Assets | 103.978 M | 252.383 M | 245.641 M | 304.449 M | 519.686 M | 511.763 M | 504.263 M | 460.490 M | |
Inventories | 10.324 M | 2.103 M | 4.320 M | 7.940 M | 9.252 M | 9.985 M | 15.135 M | 15.583 M | |
Other Current Assets | 4.091 M | 2.458 M | 2.781 M | 5.201 M | 5.911 M | 6.799 M | 8.115 M | 12.032 M | |
Short Term Investments | 4.091 M | 2.458 M | 2.781 M | 5.201 M | 5.911 M | 6.799 M | 8.115 M | 12.032 M | |
Total Receivables | 16.168 M | 20.302 M | 37.699 M | 44.793 M | 67.410 M | 78.415 M | 94.820 M | 101.434 M | |
Current Cash | 73.395 M | 227.520 M | 200.842 M | 246.515 M | 437.113 M | 416.564 M | 386.193 M | 331.441 M | |
Total Non-current Assets | 76.581 M | 86.574 M | 85.835 M | 84.730 M | 91.952 M | 89.094 M | 83.973 M | 85.238 M | |
Property Plant Equipment | 634.611 K | 626.990 K | 722.515 K | 703.000 K | 736.000 K | 971.000 K | 846.000 K | 812.000 K | |
Other Assets | 1.175 M | 12.783 M | 15.141 M | 15.628 M | 22.674 M | 21.188 M | 17.799 M | 20.687 M | |
Intangible Assets | 62.874 M | 61.268 M | 59.661 M | 58.089 M | 56.500 M | 54.893 M | 53.286 M | 51.697 M | |
Goodwill | 11.897 M | 11.897 M | 10.310 M | 10.310 M | 12.042 M | 12.042 M | 12.042 M | 12.042 M | |
Liabilities and shareholders’ equity | |||||||||
Total Liabilities and shareholders’ equity | 180.559 M | 338.958 M | 331.476 M | 389.179 M | 611.638 M | 600.857 M | 588.236 M | 545.728 M | |
Total liabilities | 165.360 M | 181.596 M | 221.920 M | 277.367 M | 332.834 M | 331.349 M | 397.259 M | 401.692 M | |
Total current liabilities | 42.570 M | 60.283 M | 96.561 M | 100.652 M | 114.974 M | 114.662 M | 138.854 M | 144.048 M | |
Accounts Payable | 19.431 M | 12.845 M | 38.605 M | 35.770 M | 42.958 M | 29.098 M | 40.679 M | 53.791 M | |
Other liabilities | 29.330 M | 27.400 M | 31.100 M | 29.100 M | 41.040 M | 31.550 M | 80.335 M | 70.000 M | |
Current long term debt | 709.120 K | 416.876 K | 424.673 K | 108.000 K | 350.000 K | 438.000 K | 1.267 M | 1.153 M | |
Long term debt | 93.459 M | 93.913 M | 94.259 M | 147.615 M | 176.820 M | 185.137 M | 178.070 M | 187.644 M | |
Other liabilities | 29.330 M | 27.400 M | 31.100 M | 29.100 M | 41.040 M | 31.550 M | 80.335 M | 70.000 M | |
Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Total Shareholder equity | 15.199 M | 157.361 M | 109.556 M | 111.812 M | 278.804 M | 269.508 M | 190.977 M | 144.036 M | |
Common stock | 39.081 M | 41.704 M | 43.515 M | 43.524 M | 43.670 M | 47.117 M | 47.390 M | 47.394 M | |
Retained earnings | -490.270 M | -535.093 M | -596.333 M | -607.551 M | -674.721 M | -736.920 M | -835.571 M | -903.928 M |